Yes, the Morningstar SP valuation is a joke on FPH. It is embarrassing that they went from $11 to $16.4. What systematic risk review are they talking about? Clearly just made something up to save face. FPH has always been a low risk business.
Their $11 valuation was too low. They failed to update it for a year. It should have been changed to $12 based just on the growth rate of around 10% in NPAT over the year and probably more from a falling NZD/USD.
Safe to say that the SP has significant support around 15.00 NZD and will only go below this on negative news from the company (re-opening of cases with Resmed for example (very unlikely)) or a broad market sell-off like we had in December 2018.
Ann: Fisher & Paykel Healthcare Reports Record Full Year Result, page-8
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add FPH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$27.84 |
Change
0.010(0.04%) |
Mkt cap ! $16.25B | |||
| Open | High | Low | Value | Volume |
| $27.62 | $27.84 | $27.35 | $10.09M | 364.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 366 | $27.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $27.85 | 1822 | 2 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| FPH (ASX) Chart |